JO
EDIT icon

John Overdeck’s Editas Medicine EDIT Stock Holding History

John Overdeck’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.32M Sell
1,332,976
-216,087
-14% -$632K ﹤0.01% 2277
2026
Q1 		$3.83M Sell
1,549,063
-83,521
-5% -$177K ﹤0.01% 2214
2025
Q4 		$3.35M Buy
1,632,584
+48,429
+3% +$140K ﹤0.01% 2063
2025
Q3 		$5.5M Buy
1,584,155
+614,229
+63% +$1.71M 0.01% 1379
2025
Q2 		$2.13M Sell
969,926
-279,849
-22% -$458K ﹤0.01% 1794
2025
Q1 		$1.45M Sell
1,249,775
-399,297
-24% -$587K ﹤0.01% 1951
2024
Q4 		$2.09M Buy
1,649,072
+290,483
+21% +$740K ﹤0.01% 1675
2024
Q3 		$4.63M Buy
1,358,589
+818,001
+151% +$3.56M 0.01% 1128
2024
Q2 		$2.52M Sell
540,588
-847,394
-61% -$4.78M 0.01% 1399
2024
Q1 		$10.3M Sell
1,387,982
-69,412
-5% -$577K 0.02% 649
2023
Q4 		$14.8M Buy
1,457,394
+192,806
+15% +$1.69M 0.03% 524
2023
Q3 		$9.86M Buy
1,264,588
+278,168
+28% +$2.39M 0.03% 611
2023
Q2 		$8.12M Buy
986,420
+277,511
+39% +$2.42M 0.02% 721
2023
Q1 		$5.14M Sell
708,909
-243,897
-26% -$2.17M 0.01% 896
2022
Q4 		$8.45M Sell
952,806
-54,249
-5% -$596K 0.03% 626
2022
Q3 		$12.3M Buy
1,007,055
+313,759
+45% +$4.89M 0.04% 430
2022
Q2 		$8.2M Sell
693,296
-248,796
-26% -$3.33M 0.03% 576
2022
Q1 		$17.9M Sell
942,092
-19,732
-2% -$367K 0.05% 414
2021
Q4 		$25.5M Buy
961,824
+583,709
+154% +$20.1M 0.05% 398
2021
Q3 		$15.5M Buy
378,115
+130,394
+53% +$7.14M 0.03% 571
2021
Q2 		$14M Sell
247,721
-566,169
-70% -$20.9M 0.03% 638
2021
Q1 		$34.2M Buy
813,890
+733,936
+918% +$41.8M 0.09% 261
2020
Q4 		$5.61M Sell
79,954
-305,225
-79% -$12.5M 0.02% 860
2020
Q3 		$10.8M Sell
385,179
-85,291
-18% -$2.78M 0.04% 479
2020
Q2 		$13.9M Buy
470,470
+91,207
+24% +$2.38M 0.07% 300
2020
Q1 		$7.52M Sell
379,263
-133,969
-26% -$3.38M 0.06% 339
2019
Q4 		$15.2M Buy
513,232
+204,564
+66% +$5.11M 0.05% 458
2019
Q3 		$7.02M Buy
308,668
+131,130
+74% +$3.25M 0.02% 699
2019
Q2 		$4.39M Buy
177,538
+151,155
+573% +$3.61M 0.01% 959
2019
Q1 		$645K Sell
26,383
-115,548
-81% -$2.62M ﹤0.01% 2104
2018
Q4 		$3.23M Buy
141,931
+110,201
+347% +$3M 0.01% 1007
2018
Q3 		$1.01M Sell
31,730
-52,394
-62% -$1.69M ﹤0.01% 1977
2018
Q2 		$3.01M Buy
+84,124
New +$2.98M 0.01% 1342

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

John Overdeck's EDIT Position: Q2 2026 in Review

John Overdeck reduced its Editas Medicine (EDIT) stake by 14% in Q2 2026, selling an estimated $632K and leaving 1,332,976 shares worth $4.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2277.

John Overdeck first reported a position in EDIT in Q2 2018 and has held it in 33 quarters since. The position peaked at $34.2M in Q1 2021. 213 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • John Overdeck held 1,332,976 shares of Editas Medicine worth $4.32M as of Q2 2026.
  • John Overdeck sold 216,087 Editas Medicine shares in Q2 2026, an estimated $632K.
  • Editas Medicine made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2277 holding.
  • John Overdeck first reported a position in Editas Medicine in Q2 2018 and has held it in 33 quarters since.
  • John Overdeck's Editas Medicine position peaked at $34.2M in Q1 2021.
  • 213 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.